Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

194.98B

Market cap194.98B

Price-Earnings ratio

25.18

Price-Earnings ratio25.18

Dividend yield

2.71%

Dividend yield2.71%

Average volume

3.30M

Average volume3.30M

High today

$365.58

High today$365.58

Low today

$357.89

Low today$357.89

Open price

$362.80

Open price$362.80

Volume

2.19M

Volume2.19M

52 Week high

$391.29

52 Week high$391.29

52 Week low

$269.77

52 Week low$269.77

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $361.33. The company's market cap stands at 194.98B, with a P/E ratio of 25.18 and a dividend yield of 2.71%.

During the trading session on 2026-07-01, Amgen(AMGN) shares reached a daily high of $365.58 and a low of $357.89. At a current price of $361.33, the stock is +1.0% higher than the low and still -1.2% under the high.

Trading activity shows a volume of 2.19M, compared to an average daily volume of 3.3M.

The stock's 52-week range extends from a low of $269.77 to a high of $391.29.

AMGN News

Investing.com 2h

Judge blocks Colorado’s first-of-its-kind price cap on Amgen’s Enbrel By Reuters - Investing.com

...

TipRanks 6h

Amgen’s AMG 133 Trial Adds a New Data Point in the Obesity Drug Race

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

Benzinga 11h

Micron, Palo Alto, Apple And A Health Care Stock On CNBC’s ‘Final Trades’

Supporting his view, Cantor Fitzgerald analyst C.J. Muse maintained Micron with an Overweight rating on June 29 and raised the price target from $1,500 to $2,00...

Analyst ratings

50%

of 34 ratings

Buy

38.2%

Hold

50%

Sell

11.8%

More AMGN News

Nasdaq 2d

Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.

Key Points Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its marketing segments in the first quarter. Amgen...

TipRanks 2d

Trial used to approve Amgen’s Tavneos retracted from NEJM

A clinical trial, originally published in 2021, which was used to approve Amgen’s (AMGN) Tavneos was retracted Monday from the New England Journal of Medicine a...

The Wall Street Journal 5d

European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked

The European Medicines Agency has called for Amgen’s Tavneos—a medication for two rare inflammatory conditions of the blood vessels—to have its marketing author...

Simply Wall St 7d

Willful Patent Verdict and Possible Treble Damages Could Be A Game Changer For Amgen

In June 2026, a Delaware jury found that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed’s Grosveld patent, awarding Harbour US$20,203,704...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.